Role of SLC xenobiotic transporters and their regulatory mechanisms PDZ proteins in drug delivery and disposition

Journal of Controlled Release

Volumn 116, Issue 2 SPEC. ISS., 2006, Pages 238-246

  Sugiura, Tomoko ^a   Kato, Yukio ^a   Tsuji, Akira ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Drug delivery; Drug disposition; PDZ proteins; Protein interaction; Transporter

Indexed keywords

DRUG PRODUCTS; MOLECULAR DYNAMICS; NUTRITION; PROTEINS; SUBSTRATES; TOXICITY;

DRUG DISPOSITION; PDZ PROTEINS; PROTEIN INTERACTION; XENOBIOTIC TRANSPORTERS;

CONTROLLED DRUG DELIVERY;

ACICLOVIR; ADEFOVIR; ALLOPURINOL; ANTINEOPLASTIC AGENT; APICAL SODIUM DEPENDENT BILE ACID TRANSPORTER; CAPTOPRIL; CARNITINE; CARRIER PROTEIN; CARRIER PROTEINS AND BINDING PROTEINS; CEFADROXIL; CEFALEXIN; CEFIXIME; ENALAPRIL; EUDRAGIT; FEXOFENADINE; L TYPE AMINO ACID TRANSPORTER 1; LEVODOPA; MONOCARBOXYLATE TRANSPORTER 1; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 1; PDZ PROTEIN; PEPTIDE TRANSPORTER 1; PRAVASTATIN; TEMOCAPRILAT; UNINDEXED DRUG; VALACICLOVIR; XANTHINE OXIDASE INHIBITOR; XENOBIOTIC AGENT; Y 700;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG EXCRETION; DRUG MECHANISM; DRUG TARGETING; DRUG TRANSPORT; GASTROINTESTINAL ABSORPTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

EID: 33845212296     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.06.009     Document Type: Article

References (74)

1. Sai Y., and Tsuji A. Transporter-mediated drug delivery: recent progress and experimental approaches. Drug Discov. Today 9 16 (2004) 712-720
2. Koepsell H., and Endou H. The SLC22 drug transporter family. Pflugers Arch. 447 (2004) 666-676
3. Mizuno N., Niwa T., Yotsumoto Y., and Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev. 55 (2003) 425-461
4. Shitara Y., Horie T., and Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci. 27 (2006) 425-446
5. Ho R.H., and Kim R.B. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 78 3 (2005) 260-277
6. Jonker J.W., and Schinkel A.H. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J. Pharmacol. Exp. Ther. 308 1 (2004) 2-9
7. Jonker J.W., Wagenaar E., Mol C.A., Buitelaar M., Koepsell H., Smit J.W., and Schinkel A.H. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol. Cell. Biol. 21 (2001) 5471-5477
8. Kato Y., Watanabe C., and Tsuji A. Regulation of drug transporters by PDZ adaptor proteins and nuclear receptors. Eur. J. Pharm. Sci. 27 (2005) 487-500
9. Anzai N., Jutabha P., Kanai Y., and Endou H. Integrated physiology of proximal tubular organic anion transport. Curr. Opin. Nephrol. Hypertens. 14 5 (2005) 472-479
10. Tsuji A., Nakashima E., Kagami I., Honjo N., and Yamana T. Effect of dose-concentration on the absorption of amoxicillin and ampicillin from the rat intestine. J. Pharm. Pharmacol. 29 (1977) 707-708
11. Tsuji A., Nakashima E., Kagami I., and Yamana T. Intestinal absorption mechanism of amphoteric beta-lactam antibiotics: I. Comparative absorption and evidence for saturable transport of amino-beta-lactam antibiotics by in situ rat small intestine. J. Pharm. Sci. 70 (1981) 768-772
12. Tamai I., Tomizawa N., Takeuchi T., Nakayama K., Higashida H., and Tsuji A. Functional expression of transporter for beta-lactam antibiotics and dipeptides in Xenopus laevis oocytes injected with messenger RNA from human, rat and rabbit small intestines. J. Pharmacol. Exp. Ther. 273 (1995) 26-31
13. Tamai I., Nakanishi T., Hayashi K., Terao T., Sai Y., Shiraga T., Miyamoto K., Takeda E., Higashida H., and Tsuji A. The predominant contribution of oligopeptide transporter PepT1 to intestinal absorption of beta-lactam antibiotics in the rat small intestine. J. Pharm. Pharmacol. 49 (1997) 796-801
14. Naruhashi K., Sai Y., Tamai I., Suzuki N., and Tsuji A. PepT1 mRNA expression is induced by starvation and its level correlates with absorptive transport of cefadroxil longitudinally in the rat intestine. Pharm. Res. 19 (2002) 1417-1423
15. Soul-Lawton J., Seaber E., On N., Wootton R., Rolan P., and Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the l-valyl ester of acyclovir, following oral administration to humans. Antimicrob. Agents Chemother. 39 (1995) 2759-2764
16. Balimane P.V., Tamai I., Guo A., Nakanishi T., Kitada H., Leibach F.H., Tsuji A., and Sinko P.J. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem. Biophys. Res. Commun. 250 2 (1998) 246-251
17. Ganapathy M.E., Huang W., Wang H., Ganapathy V., and Leibach F.H. Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem. Biophys. Res. Commun. 246 (1998) 470-475
18. Tsuji A., Tamai I., Nakanishi M., and Amidon G.L. Mechanism of absorption of the dipeptide alpha-methyldopa-phe in intestinal brush-border membrane vesicles. Pharm. Res. 7 (1990) 308-309
19. Tamai I., Nakanishi T., Nakahara H., Sai Y., Ganapathy V., Leibach F.H., and Tsuji A. Improvement of L-dopa absorption by dipeptidyl derivation, utilizing peptide transporter PepT1. J. Pharm. Sci. 87 (1998) 1542-1546
20. Nozawa T., Toyobuku H., Kobayashi D., Kuruma K., Tsuji A., and Tamai I. Enhanced intestinal absorption of drugs by activation of peptide transporter PEPT1 using proton-releasing polymer. J. Pharm. Sci. 92 (2003) 2208-2216
21. Wenzel U., Gebert I., Weintraut H., Weber W.M., Clauss W., and Daniel D. Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells. J. Pharmacol. Exp. Ther. 277 (1996) 831-839
22. Tamai I., Sai Y., Ono A., Kido Y., Yabuuchi H., Takanaga H., Satoh E., Ogihara T., Amano O., Izeki S., and Tsuji A. Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1. J. Pharm. Pharmacol. 51 (1999) 1113-1121
23. Terada T., Shimada Y., Pan X., Kishimoto K., Sakurai T., Doi R., Onodera H., Katsura T., Imamura M., and Inui K. Expression profiles of various transporters for oligopeptides, amino acids and organic ions along the human digestive tract. Biochem. Pharmacol. 70 (2005) 1756-1763
24. Tamai I., Ohashi R., Nezu J., Yabuuchi H., Oku A., Shimane M., Sai Y., and Tsuji A. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J. Biol. Chem. 273 32 (1998) 20378-20382
25. Nezu J., Tamai I., Oku A., Ohashi R., Yabuuchi H., Hashimoto N., Nikaido H., Sai Y., Koizumi A., Shoji Y., Takada G., Matsuishi T., Yoshino M., Kato H., Ohura T., Tsujimoto G., Hayakawa J., Shimane M., and Tsuji A. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat. Genet. 21 1 (1999) 91-94
26. Y. Kato, M. Sugiura, T. Sugiura, T. Wakayama, Y. Kubo, D. Kobayashi, Y. Sai, I. Tamai, S. Iseki, A. Tsuji, Organic cation/carnitine transporter OCTN2 is responsible for carnitine transport across apical membranes of small intestinal epithelial cells in mouse, Mol. Pharmacol. (in press).
27. Kobayashi D., Nozawa T., Imai K., Nezu J., Tsuji A., and Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J. Pharmacol. Exp. Ther. 306 (2003) 703-708
28. Nozawa T., Imai K., Nezu J., Tsuji A., and Tamai I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J. Pharmacol. Exp. Ther. 308 (2004) 438-445
29. Cvetkovic M., Leake B., Fromm M.F., Wilkinson G.R., and Kim R.B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27 (1999) 866-871
30. Dresser G.K., Kim R.B., and Bailey D.G. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin. Pharmacol. Ther. 77 (2005) 170-177
31. Wang W., Seward D.J., Li L., Boyer J.L., and Ballatori N. Expression cloning of two genes that together mediate organic solute and steroid transport in the liver of amarine vertebrate. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9431-9436
32. Dawson P.A., Hubbert M., Haywood J., Craddock A.L., Zerangue N., Christian W.V., and Ballatori N. The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter. J. Biol. Chem. 280 (2005) 6960-6968
33. Schwarz U.I., Seemann D., Oertel R., Miehlke S., Kuhlisch E., Fromm M.F., Kim R.B., Bailey D.G., and Kirch W. Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin. Pharmacol. Ther. 77 (2005) 291-301
34. Westphal K., Weinbrenner A., Giessmann T., Stuhr M., Franke G., Zschiesche M., Oertel R., Terhaag B., Kroemer H.K., and Siegmund W. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin. Pharmacol. Ther. 68 (2000) 6-12
35. Schwarz U.I., Gramatte T., Krappweis J., Berndt A., Oertel R., von Richter O., and Kirch W. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans. Clin. Pharmacol. Ther. 65 (1999) 283-290
36. Greiner B., Eichelbaum M., Fritz P., Kreichgauer H.P., von Richter O., Zundler J., and Kroemer H.K. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104 2 (1999) 147-153
37. Westphal K., Weinbrenner A., Zschiesche M., Franke G., Knoke M., Oertel R., Fritz P., von Richter O., Warzok R., Hachenberg T., Kauffmann H.M., Schrenk D., Terhaag B., Kroemer H.K., and Siegmund W. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Ther. 68 (2000) 345-355
38. Nishizato Y., Ieiri I., Suzuki H., Kimura M., Kawabata K., Hirota T., Takane H., Irie S., Kusuhara H., Urasaki Y., Urae A., Higuchi S., Otsubo K., and Sugiyama Y. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73 (2003) 554-565
39. Hirano M., Maeda K., Shitara Y., and Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (O.ATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther. 311 (2004) 139-146
40. Hirano M., Maeda K., Matsushima S., Nozaki Y., Kusuhara H., and Sugiyama Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol. Pharmacol. 68 3 (2005) 800-807
41. Niemi M., Backman J.T., Kajosaari L.I., Leathart J.B., Neuvonen M., Daly A.K., Eichelbaum M., Kivisto K.T., and Neuvonen P.J. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther. 77 6 (2005) 468-478
42. Matsushima S., Maeda K., Kondo C., Hirano M., Sasaki M., Suzuki H., and Sugiyama Y. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J. Pharmacol. Exp. Ther. 314 (2005) 1059-1067
43. Gonzalez D.E., Covitz K.M., Sadee W., and Mrsny R.J. An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res. 58 (1998) 519-525
44. Nakanishi T., Tamai I., Takaki A., and Tsuji A. Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. Int. J. Cancer 88 (2000) 274-280
45. Yanagida O., Kanai Y., Chairoungdua A., Kim D.K., Segawa H., Nii T., Cha S.H., Matsuo H., Fukushima J., Fukasawa Y., Tani Y., Taketani Y., Uchino H., Kim J.Y., Inatomi J., Okayasu I., Miyamoto K., Takeda E., Goya T., and Endou H. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim. Biophys. Acta 1514 (2001) 291-302
46. +-independent neutral amino acid transporter with broad substrate selectivity. J. Biol. Chem. 274 (1999) 19745-19751
47. Nawashiro H., Otani N., Shinomiya N., Fukui S., Ooigawa H., Shima K., Matsuo H., Kanai Y., and Endou H. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int. J. Cancer 119 (2006) 484-492
48. Sai Y., Kato Y., Nakamura K., Kato S., Nishimura T., Kubo Y., Tamai I., Yang S., Hu Z., Yamada I., and Tsuji A. Carrier-mediated hepatic uptake of a novel nonrenal excretion type uric acid generation inhibitor, Y-700. J. Pharm. Sci. 95 2 (2006) 336-347
49. Ishizuka H., Konno K., Naganuma H., Sasahara K., Kawahara Y., Niinuma K., Suzuki H., and Sugiyama Y. Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR). J. Pharmacol. Exp. Ther. 280 (1997) 1304-1311
50. Wang D.S., Kusuhara H., Kato Y., Jonker J.W., Schinkel A.H., and Sugiyama Y. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol. Pharmacol. 63 4 (2003) 844-848
51. Ho E.S., Lin D.C., Mendel D.B., and Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic aniontransporter 1. J. Am. Soc. Nephrol. 11 (2000) 383-393
52. Eraly S.A., Vallon V., Vaughn D.A., Gangoiti J.A., Richter K., Nagle M., Monte J.C., Rieg T., Truong D.M., Long J.M., Barshop B.A., Kaler G., and Nigam S.K. Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice. J. Biol. Chem. 281 (2006) 5072-5083
53. Sakurai Y., Motohashi H., Ogasawara K., Terada T., Masuda S., Katsura T., Mori N., Matsuura M., Doi T., Fukatsu A., and Inui K. Pharmacokinetic significance of renal OAT3 (SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritis. Pharm. Res. 22 (2005) 2016-2022
54. Sweet D.H., Miller D.S., Pritchard J.B., Fujiwara Y., Beier D.R., and Nigam S.K. Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J. Biol. Chem. 277 (2002) 26934-26943
55. Ciarimboli G., Ludwig T., Lang D., Pavenstadt H., Koepsell H., Piechota H.J., Haier J., Jaehde U., Zisowsky J., and Schlatter E. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 167 6 (2005) 1477-1484
56. Yonezawa A., Masuda S., Nishihara K., Yano I., Katsura T., and Inui K. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem. Pharmacol. 70 12 (2005) 1823-1831
57. Horikawa M., Kato Y., and Sugiyama Y. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharm. Res. 19 9 (2002) 1345-1353
58. Tsuji A., Terasaki T., Takabatake Y., Tenda Y., Tamai I., Yamashima T., Moritani S., Tsuruo T., and Yamashita J. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 51 18 (1992) 1427-1437
59. Tsuji A., Tamai I., Sakata A., Tenda Y., and Terasaki T. Restricted transport ofcyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. Biochem. Pharmacol. 46 6 (1993) 1096-1099
60. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A., van der Valk M.A., Robanus-Maandag E.C., te Riele H.P., et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77 4 (1994) 491-502
61. Gisler S.M., Pribanic S., Bacic D., Forrer P., Gantenbein A., Sabourin L.A., Tsuji A., Zhao Z.S., Manser E., Biber J., and Murer H. PDZK1: I. a major scaffolder in brush borders of proximal tubular cells. Kidney Int. 64 (2003) 1733-1745
62. Anzai N., Miyazaki H., Noshiro R., Khamdang S., Chairoungdua A., Shin H.J., Enomoto A., Sakamoto S., Hirata T., Tomita K., Kanai Y., and Endou H. The multivalent PDZ domain-containing protein PDZK1 regulates transport activity of renal urate-anion exchanger URAT1 via its C terminus. J. Biol. Chem. 279 (2004) 45942-45950
63. Kato Y., Yoshida K., Watanabe C., Sai Y., and Tsuji A. Screening of the interaction between xenobiotic transporters and PDZ proteins. Pharm. Res. 21 (2004) 1886-1894
64. Kato Y., Sai Y., Yoshida K., Watanabe C., Hirata T., and Tsuji A. PDZK1 directly regulates the function of organic cation/carnitine transporter OCTN2. Mol. Pharmacol. 67 (2005) 734-743
65. Miyazaki H., Anzai N., Ekaratanawong S., Sakata T., Shin H.J., Jutabha P., Hirata T., He X., Nonoguchi H., Tomita K., Kanai Y., and Endou H. Modulation of renal apical organic anion transporter 4 function by two PDZ domain-containing proteins. J. Am. Soc. Nephrol. 16 (2005) 3498-3506
66. +/oligopeptide transport 1. Drug Metab. Pharmacokinet. 20 (2005) 443-451
67. Wang P., Wang J.J., Xiao Y., Murray J.W., Novikoff P.M., Angeletti R.H., Orr G.A., Lan D., Silver D.L., and Wolkoff A.W. Interaction with PDZK1 is required for expression of organic anion transporting protein 1A1 on the hepatocyte surface. J. Biol. Chem. 280 (2005) 30143-30149
68. Tamura A., Kikuchi S., Hata M., Katsuno T., Matsui T., Hayashi H., Suzuki Y., Noda T., Tsukita S., and Tsukita S. Achlorhydria by ezrin knockdown: defects in the formation/expansion of apical canaliculi in gastric parietal cells. J. Cell Biol. 169 (2005) 21-28
69. Morales F.C., Takahashi Y., Kreimann E.L., and Georgescu M.M. Ezrin-radixin-moesin (ERM)-binding phosphoprotein 50 organizes ERM proteins at the apical membrane of polarized epithelia. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 17705-17710
70. Kocher O., Comella N., Gilchrist A., Pal R., Tognazzi K., Brown L.F., and Knoll J.H. PDZK1, a novel PDZ domain-containing protein up-regulated in carcinomas and mapped to chromosome 1q21, interacts with cMOAT (MRP2), the multidrug resistance-associated protein. Lab. Invest. 79 (1999) 1161-1170
71. Kikuchi S., Hata M., Fukumoto K., Yamane Y., Matsui T., Tamura A., Yonemura S., Yamagishi H., Keppler D., Tsukita S., and Tsukita S. Radixin deficiency causes conjugated hyperbilirubinemia with loss of Mrp2 from bile canalicular membranes. Nat. Genet. 31 (2002) 320-325
72. Shitara Y., Hirano M., Sato H., and Sugiyama Y. Gemfibrozil and its glucuronideinhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 311 (2004) 228-236
73. van Tellingen O., Buckle T., Jonker J.W., van der Valk M.A., and Beijnen J.H. P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo. Br. J. Cancer 89 (2003) 1776-1782
74. Wijnholds J., deLange E.C., Scheffer G.L., van den Berg D.J., Mol C.A., van der Valk M., Schinkel A.H., Scheper R.J., Breimer D.D., and Borst P. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J. Clin. Invest. 105 (2000) 279-285